Discovering New Drugs Through Continuous Research and Development

Greetings

Komipharm first became interested in arsenic compounds as therapeutic agents in the early 1980s and has been collaborating with the world’s leading researchers to realise ideas for drug development ever since.

With the goal of becoming a global pharmaceutical company, we established Komipharm International Australia in March 2015 and are leading overseas clinical studies.

Komipharm’s drug development goals include:

1. Developing the world’s first new drug to reduce and replace opioid painkillers while treating metastatic cancer.
2. Developing a new drug for the treatment of cancer metastasised to the brain from lung and breast cancer (drug substances with 98% passage through the blood-brain barrier (BBB)).
3. Developing a new drug to treat glioblastoma (GBM).

We aim to contribute to the value of investment by developing new drugs that are orally administered and can be used for home healthcare without hospitalisation, thereby contributing to the reduction of medical expenses for the country and its citizens.
Komipharm is committed to protecting our customers and employees. Guided by our values-based culture, we take precautions to keep our employees and facilities safe so we can continue to fulfill our commitment to our customers and public health.